1

Hamza Mujagic MD., MSc., Dr. Sc. March 15. 2011.Visiting Professor of Oncology and HematologyHarvard UniversityMassachusetts General HospitalBoston, USA.

Phone in Bosnia: 387 35 226 383 Mobile phone: 387 62 415 728hmujagic@yahoo.comhmujagic43@gmail.com Currently residing in Bosnia

A SUMMARY OF CV IN 10 SENTENCES

Dr Mujagic is Visiting Professor of Oncology and Hematology and Scholar at Massachusetts General Hospital and Harvard University, former Institutional Review Board Member for Harvard University Cancer Center, Boston and former Consultant for Xanthus Pharmaceuticals, Cambridge, Massachusetts, USA. He graduated from the University of Zagreb Medical School in 1968 where he also received his basic clinical training. He obtained his Masters degree from the University of Zagreb in 1973 and his PhD from the Universities of Essen, Germany and Zagreb in 1976. He received his specialty training in Internal medicine in Europe and from the University Medical Center in Sarajevo 1980. He worked at Institute Rudjer Boskovic, University of Zagreb, from 1969-1971 and Central Institute for tumors in Zagreb from 1971-1977, University surgical clinic in Essen from 1972-1973, the National Cancer Institute of the USA in Bethesda from 1978-1984, at the Memorial Sloan-Kettering

2

Cancer Center, New York, from 1984-1985, at the Universities in Banjaluka and Tuzla and as a Visiting Professor at the Massachusetts General Hospital and Harvard University from 1998. He currently divides his time between Boston, USA and Tuzla, Bosnia. He is specialist in Internal Medicine/Oncology and is Professor of Medicine and Oncology. He published 96 research papers, is or was member of editorial boards of 4 international medical journals, reviewer for several prestigious scientific journals and is cited 200 times around the globe. His areas of expertise are: Melanoma, Clinical trials and Cancer Pharmacology.

SKILL-ORIENTED CV

This CV documents my knowledge of Oncology, clinical research experience, management and analytical skills in Clinical trials and drug analysis and reporting.

WHAT I DO BEST

1.Taking care of cancer patients, especially melanoma, breast, lung, GI and urologic.2.Design, monitoring and reporting of Clinical trials.3.Medical drugs analysis and writing.

SKILLS

1.Diagnostic procedures in solid tumors, chemotherapy and aggressive chemotherapy with bone marrow transplantation, immunotherapy of solid tumors and genetic tests for individualized therapy.

2.Monitoring and procedures with Clinical Research Protocols, former member of Dana Farber/Harvard University Cancer Center Institutional Review Board.

3.Knowledge and experience in Clinical Research Methodology, Protocoland Study design and Medical terminology and Administration accumulatedat Massachusetts General Hospital/Harvard University and XanthusPharmaceuticals, Boston and Cambridge, Memorial Sloan-Kettering CancerCenter, New York, NY and National cancer Institute, Bethesda, Maryland.

3

4.Three decades of experience in phase I, II and III Clinical trials.

5.Three years of experience in Adverse Drug Reactions, Drug Interactions, and drug Safety and Reporting as a reviewer of clinical protocols at Harvard University Cancer Center. 6.Clinical development of oral fludarabine monophosphate (2F-ara-AMP) second line in patients with CLL for Xanthus Pharmaceuticals, Cambridge.

7.Strong organizational, interpersonal and communication skills, and good management skills with attentions to details, and hidden pitfalls. Accustomed to prioritize and meet aggressive deadlines.

8.A polyglot (besides English speaks German, and all slavic languageswith computer skills: Microsoft Word, Microsoft publishing, Adobeprofessional, Adobe Photoshop, SPSS, Statistica, Stata, Outlook and Excel.

EXPERIENCE

07/2005-present Boston, USA Massachusetts General HospitalHarvard University,Visiting Professor, Scholar,and Ribakoff Fellow.

Fellowship in Genitourinary Oncology, The Bertucci Center for GenitourinaryCancers.

Revision of systems and protocols monitoring adverse drug reactions forDana-Farber/Harvard Cancer Center.

Assist in clinical monitoring of subjects for Phase I-III Clinical ResearchStudies within departments of Genitourinary Oncology and MedicalGynecology at the Massachusetts General Hospital Cancer Center.

Analysis and reporting data about “carcinoma in situ” of breast cancerpatients.

4

Active participation in four Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center Clinical Research Courses:

1.Design and Conduct of Clinical Trials.

2.Statistical Methods for Clinical Investigators.

3.Tumor measurements.

4.CITI Program and Exam for Protection of Research Subjects.

5

07/2003-12/ 2003 Boston, USA Massachusetts General HospitalHarvard University,Visiting Scholar and ClinicalResearch Fellow.

Participation in the following Clinical trials at The Dana-Farber/Harvard

Cancer Center:

1.A phase I trial of PT523 in patients with solid tumors.

2.PS 341 in patients with solid malignancies.

3.CP868596 Dose escalation Study to evaluate Safety.

4.Review of data about dose intensity and dose density distributions ofchemotherapy in elderly cancer patients.

5.Writing papers about thalidomide and its metabolites.

11/2000-3/2001 Boston, USA.

Massachusetts General HospitalHarvard University,Visiting Scholar and Fellowin Medicine.

Participation in Clinical Trials of aggressive chemotherapy and bone marrowTransplantation.

01-06/1997.University Clinic of Marburg Oncology/Hematology/ImmunologyPhilipps University Marburg. GermanyVisiting Professor.

Active participation in Clinical Trials of aggressive chemotherapy and bone

6

marrow transplantation in patients with hematologic malignancies.

Consulting in chemotherapy and hormonal therapy of patients with solidtumor malignancies.

06/1994-07/2005. Tuzla, Bosnia

University of Tuzla,Tesanj General Hospital,Gracanica General Hospital.Professor and HeadOf Oncology and Pathophysiology

Analysis and interpretation of Clinical data and reporting end results.

Clinical work with patients enrolled in actual Clinical Trials.

Teach and train undergraduate students, doctors and nurses about designand conduct of Clinical Trials in Oncology.

07/1985-07/1992 Banjaluka, Bosnia

University of BanjalukaAssociate Professor of Medicine andDirector of Clinical OncologyServices.

Initiation, organization, monitoring and managing phase I-III ClinicalTrials in Oncology.

Actual clinical work with cancer patients.

Organization of pre-study, site initiation and investigator meetings.

Review Clinical Trials submitted from other institutions.

Taught students, fellows, researchers, pharmaceutical representatives andnurses in design and conduct of Clinical trials.

7

07/1984-07/1985 New York, NY

The Memorial Sloan-KetteringCancer Center/CornellUniversity, New York.Fellow in Oncology

Active participation in Clinical trials and taking care of cancer patients.

1.Intralesional non-specific immunotherapy with “Detox” vaccine inmalignant melanoma patients.

2.Immunotherapy with Interferon gamma in kidney cancer patients.

3.Managing hyperphosphatemia in breast cancer patients.

Teaching residents in Immunotherapy Trials.

01/1980-07/1984 Bethesda, Maryland National Institutes of Health, National CancerInstitute, Clinical PharmacologyBranch.Visiting Scientist/Consultant Expert

Clinical Research work in Cancer pharmacology andImmunology.

1.Discovering the effects of Vinca alkaloids on cell skeleton.

2.Phenotypic changes in myeloma cells in vitro.

3.Drug resistance/sensitivity of breast cancer cells in vitro.

4.Cell culture, immunologic techniques, and drug research techniques.

07/1977-12/1980 Sarajevo, Bosnia

8

University Medical Center.Head of the departmentOf Oncology, Consultant inOncology, Head melanoma andSkin cancer unit.

Design, organization and conduct of a clinical trial of non-specificimmunotherapy in malignant melanoma patients.

In collaboration with the Ministry of Health of Bosnia organized first trial in chemotherapy of lung cancer patients.

Taking care of cancer patients.

01/1972-07/1977 Zagreb, Croatia

The Central Institute for tumorsand Allied Diseases.Clinical Associate, ClinicalResearch Scientist and Headof Tumor Immunology

Authored and executed the first Clinical trial of BCG Immunotherapy inmalignant melanoma patients.

Developed study protocols, developed study-related materials including case report forms, deviation from protocols, etc.

Participated in development of chemotherapy protocols for patientswith solid malignancies.

Introduced Clinical Immunotherapy methods and immunologicaltechniques in vitro.

Development of skin testing protocols with the German Clinical tumorcenter, University of Essen and Central Institute for tumors

01/1970-07/1972 Zagreb, Croatia

9

The Institute of Natural Sciences“Rudjer Boskovic”. University of Zagreb

Education (experimental and clinical combined) in translationalresearch as a first candidate in former Yugoslavia.

Developed and executed Clinical Trial of active specific immunotherapyin ovarian cancer patients.

Irradiated tumor cells and prepared vaccines individually for each patient.

Developed a test “Experimental lung metastases of fibrosarcoma” in C57BL mice.

EDUCATION

2005-2007 Massachusetts General Hospital/Harvard University, Boston MA.

Fellowship in Genitourinary Oncology, Clinical Trials, Adverse drugreactions and safety.

2003- 2004 Massachusetts General Hospital/Dana-Farber Cancer Institute/Harvard University, Boston MA.

Clinical trials with anti-tumor vaccines. Drug writing and reporting.

2000-2001Massachusetts General Hospital/Harvard University, Boston MA.

Clinical trials in aggressive chemotherapy and bone marrow transplantation. Drug writing and reporting.

1998-1999University Hospital, Marburg, Germany.

Clinical trial in aggressive chemotherapy and bone marrowTransplantation.

1994-1995The Memorial Sloan-Kettering Cancer Center, New York, NY.

10

Fellowship in Medical Oncology, Clinical trials in melanoma and kidneycancer immunotherapy. Clinical trial in hyperphosphatemia in breastcancer patients.

1979-1985The National Institutes of Health, National Cancer Institute, Clinical Pharmacology Branch, Bethesda, Maryland.

Cancer pharmacology and laboratory research. Diagnostic trial in drugresistance.

1982 ECFMG exam (equal to USMLE).Educational Commission For Foreign Medical Graduates, Philadelphia.

1984 FMGEMS clinical exam (Foreign Medical Graduate Examination in Medical Science).Educational Commission For Foreign Medical Graduates Philadelphia.

1979 National Institutes of Health, National Cancer Institute, Laboratory ofImmunodiagnosis, Bethesda, Maryland.

Immunologic research methods.

1974 The Swiss Institute for Cancer Research, Lausanne, Switzerland.

Clinical Cancer Research Course.

1974 Rumanian National Cancer Institute, Bucharest, Romania.

Cancer Radiobiology.

1973-1974 German Clinical Tumor Center, University of Essen, Germany.

Residency in Medical and Surgical Oncology.

11

1977-1980 University Medical Center Sarajevo, Bosnia.

Residency in Internal Medicine.

1972-1976 The Central Institute for Tumors And Allied Diseases, Zagreb, Croatia.

Clinical Associate.

1972-1975 University of Essen, Germany, University of Zagreb, Croatia.

Doctor of Sciences and Philosophy.

1969-1971 Postgraduate assistant, Master of Sciences. Institute Rudjer Boskovic,Center for Advanced Studies, University of Zagreb, Croatia.

1968-1969 University Hospital “Sisters of Mercy”, Zagreb, Croatia.

Internship.

1963-1968 Medical Faculty University of Zagreb, Croatia.

Doctor of Medicine.

Computer skills:

Microsoft word and Publishing, Adobe programs, SPSS, Clinical Trials, E-trials portal, Excel, etc.

BRIEF CHRONOLOGY OF EMPLOYMENT

1968-1969Internship, University Hospital Zagreb, Croatia.

1969-197O Physician in commissioned Military Service.

197O-1971Postgraduate Research Assistant in Oncology, Institute “Rudjer

12

Boskovic,”University of Zagreb, Croatia.

1971-1977 Clinical Research Assistant and Scientist, Head of Tumor ImmunologyGroup and Clinical Associate The Central Institute for Tumors, andAllied Diseases, Zagreb, Croatia.

Head, Department of Oncology and chief, Division of Chemotherapy andImmunotherapy, The Institute of Radiology and Oncology, UniversityMedical Center Sarajevo, Bosnia.

198O-1985 Visiting Scientist, Clinical Oncology Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of of Health,Bethesda, USA.

1984-1985Clinical Fellow in Oncology, The Memorial Sloan-Kettering Hospital forCancer and Allied Diseases, New York, NY.

1986-1990Head of Malignant Melanoma and Skin Tumors Unit, The Clinic for Plastic and Reconstructive Surgery, University Medical Center Sarajevo, Bosnia.

1986-1992Head of Oncology, Assistant Professor of Pathologic Physiology, Associate Professor of Medicine and Oncology, The Clinical andUniversity Hospital Center, University of Banjaluka, Bosnia.

1994-2006 Professor and Chair of Oncology and of Pathologic Physiology, MedicalFaculty University of Tuzla, Bosnia. Professor of Molecular Oncology at Postgraduate Studies, Medical faculty University of Tuzla, Bosnia.

2000-2005 Visiting Scholar and Clinical Research Fellow in Medicine Massachusetts General hospital and Harvard University, Boston, USA.

13

2005- Visiting Professor and Scholar, Massachusetts General hospital andHarvard University, Boston, USA.

INTERNATIONAL DIPLOMAS AND CERTIFICATES

ECFMG, Educational Committee for Foreign Medical Graduates, Philadelphia, Pennsylvania, USA, Diploma.

FMGEMS, Foreign Medical Graduates Examination in Medical Sciences, Certificate of Clinical Part.

Massachusetts General Hospital and Harvard University, Ribakoff Fellowship in Genitourinary Oncology, Diploma.

National Institutes of Health, National Cancer Institute, Diploma.

Massachusetts General Hospital and Harvard University, Design and Conduct of Clinical Trials, Certificate.

Massachusetts General Hospital and Harvard University, Statistical Methods for Clinical Investigators, Certificate.

Massachusetts General Hospital/University of Miami, ICTI-Program for Protection of Research Subjects, Certificate.

Dana-Farber Cancer Institute and Harvard University, Tumor Measurements, Certificate.

PUBLICATIONS

Total number of publications: 96.

1. Papers in peer-reviewe Journals: 47.

2. Papers from International Congresses: 38

2. Chapters in USA books: 5

3. Chapters in other international books: 1.

4. Domestic books: 5.

KNOWLEDGE OF LANGUAGES

14

English, and German(speaks fluently, reads, and writes).

French, Italian, and Russian(reads, and understands).

Speaks and understands several Balkan languages and dialects.

BOARD CERTIFIED SPECIALTIES

Internal Medicine (former Yugoslavia).Urologic Oncology (Massachusetts General Hospital), Boston, USA.

EXPERTISE

1. The design and conduct of phase I-III Clinical trials.

2. New anticancer drugs and adverse reactions.

3. Cancer Pharmacology and Immunology

RESEARCH INTEREST

Melanoma. Phases I-III Controlled Clinical Trials.

MEMBERSHIP IN EDITORIAL AND ADVISORY BOARDS

Regional Editor, Croatian Medical Journal.

Former Member of the Editorial Board of “The Oncologist”, USA.

Member of Editorial Board: Journal of Clinical and Biological Sciences, Afrfica.

Former Member of the Editorial Board of “Libri Oncologici”.

Former Associate Editor of “Acta Medica Saliniana.

MEMBERSHIP IN PROFESSIONAL AND SCIENTIFIC ASSOCIATIONS

1.Senior Member of USA Society of Clinical Oncology.

2.Member of World Oncology Network.

3.Former Member of Croatian Immunological Society.

15

4.Former Member of European Organization for Research and Treatment of Cancer EORTC.

5.Former Member of European Association for Research on Cancer EACR.

6.Former Member of Cell Kinetics Society, USA

AWARDS AND RECOGNITIONS

1.Fellowship of the Scientific Fund of the Republic of Croatia.

2.Cancer Expert for East European Countries.

3.Member of World Health Organization Malignant Melanoma Committee.

4.ICRETT Award (Awarded by the International Union Against Cancer, Geneva, Switzerland).

5.Cited in catalogs of best cancer specialist in the North America (ASCO, WON, Sloan-Kettering).

6.Member of „Marquis Who is Who in the World“, most influential 2000 scientists.

7.Senior Member of the New York Academy of Sciences, USA.

8.Ribakoff Award for Excellence, Massachusetts General Hospital, Harvard University, Boston, USA.

PRESENT EMPLOYMENT:

Visiting Professor of Oncology and Hematology, Massachusetts General Hospital and Harvard University Medical School, Boston, MA, USA.

CAREER SYNOPSIS

I started my professional career in 1970 as a Postgraduate assistant in the Rudjer Boskovic Institute of Natural Sciences at the University in Zagreb, Croatia. I was the first candidate selected by the Institute to be educated in translational research. I worked in the laboratory

16

of tumor immunology and at the University hospital Merkur. My primary responsibility was to organize and conduct the first clinical trial in Europe of specific immunotherapy in ovarian cancer patients. I prepared a vaccine consisting of irradiated ovarian cancer cells mixed with Freund’s adjuvant and injected patients with the vaccine subcutaneously three times at weekly intervals. I treated 35 patients and observed no significant clinical results.

After two years I was invited to the newly organized Central Institute for Tumors and Allied Diseases in Zagreb and I established there a laboratory of Clinical tumor Immunology. I worked in that institution for seven years as a Clinical research assistant, Clinical associate and Head of Tumor immunology. My responsibilities were to organize clinical trials in the fields of Immunotherapy and Chemotherapy. I wrote several clinical research protocols, organized the first clinical trial of immunotherapy for malignant melanoma, a clinical trial of immunotherapy in ovarian cancer patients, and trial of immune-chemotherapy in bronchial cancer and soft tissue sarcoma patients. As immunopotentiators I used BCG, Corynebacterium parvum and Lactobacillus acidophilus. I also introduced several investigative chemotherapy protocols especially in breast and lung cancer patients. During my work at the Central Institute for tumors in Zagreb, which served as the Central oncological institute for Croatia, I went twice to the German Clinical Tumor Center at the University in Essen. There I started my PHD dissertation which I finished at my home institution in Zagreb. In Germany I was again engaged in clinical trials at surgical and medical clinics conducting clinical research of immune mechanisms in cancer patients.

After seven years in Zagreb I moved to the University Medical Center in Sarajevo, Bosnia, where I finished my residency and Board certification in Internal medicine. There I organized the Department of Clinical Oncology and Division of Chemotherapy and Immunotherapy and became the Head of the Department of Oncology. In collaboration with the Ministry of Health of Bosnia and the Physicians Chamber. I authored first clinical program in oncology and organized and conducted the country’s first clinical trials in chemotherapy for lung cancer patients. I also introduced standard chemotherapy protocols that at that time were in use in the United States and in Western Europe. In 1977 I wrote and introduced

17

informed consents in clinical practice for the first time in South Europe.

In 1978 I was selected as a UICC Fellow for the first Course in Experimental Cancer Research in Europe in Lausanne, Switzerland. A year later as a recipient of ICRETT (International Cancer Research Technology Transfer Award) of UICC I spent six months at the National Cancer Institute in Bethesda in Laboratory of Immunodiagnosis being occupied with isolation and characterization of tumor-specific antigens. Upon an invitation from Bruce A Chabner MD, Direcror of the Division of Cancer Treatment, NIH, NCI and Charles M. Myers, Head of Clinical Pharmacology, NIH, NCI, I returned to the same institution in 1980 to work for four years in the cell kinetics section of the Clinical Pharmacology Branch, Division of Cancer Treatment of the National Cancer Institute. I primarily worked with cytoskeleton models and I elaborated a test of cytoskeletal decoration with monoclonal anti tubulin antibodies that made it possible to visualize vinca alkaloid-induced cytoskeletal changes.

At the end of 1984 I accepted a highly competitive fellowship in Clinical Oncology from the Memorial Sloan-Kettering Cancer Center in New York. I spent one year working in the area of clinical trials. At Memorial I was responsible for the conduct of two clinical trials: The use of DETOX vaccine for intralesional immunotherapy of malignant melanoma patients and the use of IFN in immunotherapy of kidney cancer patients. I also was involved in a clinical trial to treat hypercalcemia in breast cancer patients. In addition, together with Dr. Alan Houghton we prepared the first monoclonal antimelanoma antibody and I was honored to introduce the very first infusion to a melanoma patient. I was also responsible for the treatment of Kaposi sarcoma patients with intratumoral injection of DETOX vaccine. It was at the Memorial where I first started to be deeply interested in clinical trials.

In 1985 I left New York, USA and went to Bosnia. I wanted to take a part in preparing Bosnian people for their struggle for freedom and to take a part in defending my home country. I organized clinical oncology services at the University Medical Center in Banjaluka. I taught my associates design and conduct of clinical trials and educated 12 physicians and 25 nurses specialized in the conduct of

18

clinical trials in medical oncology. I established standard protocols and systems to monitor chemotherapy effects and side effects.

Because of the aggression of Serbian chetnik paramilitary militia on Bosnia in June 1993 I was forced under immediate life threatening conditions to leave the city of Banjaluka and I settled a year later in Tuzla, Bosnia. There I taught under-graduate and post-graduate students in Pathologic physiology and Medical Oncology. I lectured about design and conduct of clinical trials at the University and hospitals. For several years I was privately engaged in the conduct of clinical trials with IL-2 in melanoma patients.

In 1997 I spent a half year as a Visiting Professor at the Oncological Clinic/University of Marburg/Germany working on autologous and allogeneic bone marrow transplantation in patients with hematologic malignancies.

During the period from 1998 to 2008 I was privileged to spend 4 sabbaticals as a clinical researcher, Visiting Professor and lately as the Visiting Professor and Scholar of Oncology and Hematology at the Massachusetts General Hospital/Dana Farber/ Harvard University Cancer Center. During these years I worked closely with Dr. Bruce A. Chabner, the Clinical Director of the MGH/Harvard Cancer Center. In i998-2000 I was engaged mostly in a trial of a cell-based vaccine in prostate cancer patients at the Dana-Farber Cancer Center. In 2003 I wrote a chapter about thalidomide and was engaged in the area of aggressive chemotherapy and bone marrow transplantation in patients with hematologic malignancies. In 2005 I served as a Ribakoff fellow in genitourinary oncology, and became responsible for revising systems monitoring adverse drug reactions in Dana-Farber/MGH trials. Most of 2006 I spent working on drug safety and pharmacovigilance for Harvard Cancer Center. In November of 2006 I was appointed as a Consultant for malignancies for Xanthus Pharmaceuticals, Cambridge. I was especially engaged in developing oral formulation of fludarabine monophosphate and in work with chronic lymphocytic leukemia and myelodysplastic syndromes. I prepared IND and NDA as well as orphan drug applications for fludarabine monophosphate in chronic lymphocytic leukemia. I completed a series of 5 didactic courses at the Harvard University/MGH in the area of clinical trials or closely related to clinical trials.

19

SELECTED PUBLICATIONS

Entrez PubMed, www.ncbi.nlm.nih.gov/entrez (type in Mujagic H)

Science Citation Index Expanded, www.portal.isiknowledge.com (type in Mujagic H).

Biosis, www.gateway.ut.ovid.com , (type in Mujagic H).

EMBASE, www. embase.com, etc.

LIST OF PUBLICATIONS

A.Chapters in international books

1. Bruce A. Chabner, Jeffrey Barnes, Joel Neal, Hamza Mujagic, Lecia Sequist, Wyndham Wilson, and Dan L. Longo: Chapter 62 Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal antibodies, and Cytokines, in: Goodman and Gillman, The Pharmacological Basis of Therapeutics, McGraw-Hill Co., 2010.

2. Mujagic Hamza: Thalidomide and its analogs, in: Harrisons Handbook of Oncology, Editors: B A Chabner, D L Longo and T Lynch, The McGraw Hill Co. 2007.

3. Mujagic Hamza and Bruce A Chabner: The Taxanes. In: Harrisons Handbook of Oncology, Editors: B A Chabner, D L Longo and T Lynch, The McGraw Hill Co, 2007.

4. Supko GJ, Puchalski AT, Mujagic H, Zhu AX, Chabner BA. Clinical Pharmacology of Anticancer Drugs. Handin RI, Lux SE, Stossel TP, eds. Handin’s Textbook of Hematology. Lippincott Williams & Wilkins, 2002: 2095-2133.

5. Curt GA, Allegra CJ, Fine RL, Mujagić H, Yeh GC, Chabner BA. Cancer Chemotherapy. Ulmann’s Encyclopedia of Chemistry. VCH Verlagsgesellschaft, 1986; A5: 1-28.

6. Silobrčić V, Milas L, Mujagić H. Experimental lung metastases as a test in tumour immunology. Doll R, Vodopija I, eds. Host

20

environmental interactions in the ethyology of cancer in man. WHO IARC, 1972: 411-417.

B.Books

1. Mujagić H. Practical Pathologic Physiology, University of Banjaluka 1987.

2. Mujagić H. Selected chapters from Pathologic Physiology,University of Banjaluka 1988.

3. Nurkić M, Mujagić H. Immunological dictionary,University of Tuzla 2001.

4. Mujagić H, Radovanović Z, Cuculić M, Vujanović N, Vujić A, Čobić P. The acquired immunodeficiency syndrome-AIDS: Svjetlost- Sarajevo, 1988.

5. Mujagić Hamza, Mujagić Zlata: Agressiveness of tumor disease, Hamidovic,Tuzla, 2003.

C.Peer-reviewed publications

1. Milas L, Mujagić H. Protection by Corynebacterium parvum against tumor cells injected intravenously. Europ J Clin Biol Res 1972; 17: 498-500.

2. Milas L, Mujagić H. The effect of splenectomy on fibrosarcoma metastases in lungs of mice. Int J Cancer 1973; 11: 186-190.

3. Mujagić H, Krušić J, Dešković M, Malenica B. Immunological reactivity to non-specific antigens in cervical carcinoma patients. Period Biol 1976; 78: 151-153.

4. Mujagić H, Nola P, Malenica B, Maričić Ž, Allegretti N. Immunological reactivity in colorectal carcinoma patients with special reference to the new classification of carcinomas of colon and rectum. Period Biol 1976; 78: 153-155.

5. Mujagić H, Mažuran R, Malenica B, Silobrčić V. Clinical detection of cellular immunity to melanoma-specific antigens in men by the monocyte spreading inhibition test: correlation between in vivo and in vitro immunological test parameters. Period Biol 1976; 78: 156-157.

21

6. Mažuran R, Mujagić H, Malenica B, Silobrčić V. In vitro detection of cellular immunity to melanoma antigens in men by the monocyte spreading inhibition test. Int J Cancer 1976; 17: 14-20.

7. Rogan J, Mujagić H, Malenica B. Lymphocyte cytotoxicity to malignant melanoma and cervical carcinoma cells. Period Biol 1976; 78: 155-156.

8. Malenica B, Mujagić H, Kolarić K, Radetić M, Maričić Ž, Roguljić A, Rogan J, Vukas D. BCG immunotherapy in metatsatic malignant melanoma. Period Biol 1976; 78: 158-159.

9. Mujagić H.The chemotherapy of gastric carcinoma.The Medical Herald 1978;14:71-76.

10.Mujagić H, Kolarić K, Malenica B, Nola P. BCG immunotherapy in previously treated malignant melanoma patients. Biomedicine, 1979; 30: 95-102.

11.Mujagić H. Immunotherapy with BCG: an attempt at standardization of methods based on our experience and results. Period Biol 1980; 82(2): 195-205.

12.Mujagić H, Dešković M, Malenica B, Bistrović M, Krušić J. The significance of tuberculin immunity testing in cancer patients (invited article). Cell Molec Biol 1980; 26: (2):111-123.

13.Mujagić H, Chen SS, Geist R, Occhipinti SJ, Conger BM, Smith CA, Schuette WH, Shackney SE. Effects of Vincristine on Cell Survival, Cell Cycle Progression, and Mitotic Accumulation in asynchronously growing Sarcoma 180 Cells. Cancer Res 1983; 43: 3591-3597.

14.Mujagić H, Conger BM, Smith CE, Occipinti SJ, Shuette WH, Schackney SE. Schedule dependence of Vincristine lethality in sarcoma 180 cells following partial synchronisation with Hydroxiurea. Cancer Res 1983; 43: 3598-3603.

15.Malenica B, Mujagić H, Popović S, Eljuga D, Allegretti N, Rogan-Grgas J. Immunocompetence in patients with malignant melanoma. Period Biol 1983; 16: 351-353.

16.Shuette WH, Chen SS, Occipinti SJ, Mujagić H, Shackney SE. Automated radioautographyc grain counting: correction for grain overlap. Cell Tissue Kinet 1983; 16: 221-227.

22

17.Mujagić H, Shackney CE, Smith CE, Chen SS. Quantitative changes in surface immunoglobulin expression in WEHI-231 lymphoma cells in relation to their proliferative rate. Oncology, 1986; 43: 237-242.

18.Krnjajić N, Jevrić A, Krnjajić Z, Filipović I, Mujagić, H. Comparison of PGE and PGE2 levels in pregnant syngeneic Balb/c mice with transplanted fibrosarcoma. Prog Clin Res 1987; 242: 119-122.

19.Mujagić H, Krnjajić N, Jevrić A. The levels and relations of prostaglandins in pregnant and non-pregnant tumor-bearing mice. J Cancer Res Clin Oncol 1989; 115: 383-387.

20.Mujagić H. Aggressive chemotherapy and sensitivity persistance to anticancer drugs.Ann Paul Debre Hosp 1990; 41: 7-15.

21.Mujagić H, Mujagić Z. Detection of pleyotropic drug resistance by the rapid immunofluorescence assay of drug effects on cell skeleton. Oncology 1991; 48(3): 202-209.

22.Mujagić H, Blitvić A, Omeragić F. I can see you but you can not see me. Updates 1999; 1(3): 4 -11.

23. Mujagic H, Chabner BA. Thalidomide. MD Vista J Med 2001; 4: 1-7.

24.Mujagić H, Chabner BA, Mujagić Z. The mechanisms of action and potential therapeutic uses of thalidomide. Croat Med J. 2002; 43(3): 274-285.

25.Mujagić Z, Mujagić H. Circulating levels of prolactin as an indicator of effectiveness of therapy in breast cancer patients. Int J Cancer 2002; Suppl 13: 216.

26.Mujagić Z, Mujagić H. Prolactin–new tumor marker for breast cancer? Turk J Biochem 2003; 28 (3): 120-121.

27.Mujagic Z, Mujagic H. Importance of serum prolactin determinations in metastatic breast cancer patients. Croat Med J. 2004; 45(2): 176-180.

28.Mujagic Z, Mujagic H. The relationship of circulating prolactin levels to the size of primary tumor in breast cancer patients. Turk J Biochem. 2004; 29 (4): 277-281.

23

29.Pranjic N, Mujagic H. Gasoline sniffing and lead toxicity in workers at gasoline stations. J Occup Env Med. 1998; 40(11): 1024-1029.30.Mujagić H, Malenica B, Nola P, Maričić Ž, Kolarić K. BCG immunotherapy applied after surgery in malignant melanoma patients. The Med Rev, Galenika 1976; 16: 42-48.

31.Mujagić H, Roth A, Smudj K, Malenica B, Juzbašić S. Immunotherapy and chemotherapy in the treatment of advanced osteosarcoma–A case report. Iugosl Orthopaed Acta 1977; 2: 209-213.

32.Mujagić H. The possibilities of immunotherapy of malignant tumors in men. Med Arch 1978; 32: 43-49.

33.Mujagić H. The monitoring of lymphocyte blast specific and non-specific transformation in malignant melanoma patients and the possibilities of clinical utilisation of results. Radiol Jugosl 1978; 12: 794-804.

34.Krnjajić N, Jevrić A, Petronijević S, Krnjajić Z, Mujagić H. PGE2 levels in pregnant syngeneic BaLb/c mice with transplanted methylcholanthrene fibrosarcoma. Iugoslav Physiol Pharmacol Acta, 1985; 21 (3): 191-192.

35.Pertonijević S, Krnjaić N, Jevrić A, Mujagić H. PGF2 alfa levels in pregnant syngeneic BALB/c mice with transplanted methylcholantrene fibrosarcoma. Iugoslav Physiol Pharmacol Acta 1985; 21(suppl.3)p. 66.

36.Mujagić H. Morphological changes in cell skeleton caused by anticancer drugs. Inform karcinog 1990; 7: 9-23.

37.Pjanić A, Unčanin D, Sarajlić O, Abaspahić E, Mujagić H. Detection of cellular immunity in gastrointestinal carcinoma patients by the leucocyte adherence inhibition assay. Scripta Medica, 1991; 22: 10-16.

38.Šabanović Z, Mujagić H, Bazrdjanović M. Quality of medical records as a basis for DRG classification in the health care system in

24

Bosnia and Hercegovina. Med Arch 1999; 53 (suppl 3): 61-64.

39.Ljuca Dž, Fatušić Z, Mujagić H, Ljuca F, Alispahić N. Precarcinoma and early carcinomatous lesions in the uterine cervix and the use of oral contraceptives. Med Arch 2000; 54 (2): 71-73.

40.Pranjić N, Mujagić H, Nurkić M, Karamehić J, Pavlović S. Assessment of health effects in workers at gasoline stations. Bosnian Journal of Basic Medical Sciences 2002, 2 (1-2): 35-45.

41.Pranjić N, Mujagić H, Pavlović S. Inhalation of gasoline and damage to health in workers at gasoline stations. Med Arch 2003; 57 (1): 17-20.

42.Mujagić H, Prnjavorac B, Mujagić Z, Festa G. Alcohol in alcoholic liver disease is a causative factor for development of allergic skin manifestations. Med Arch 2003; 57 (5-6): 273-278.

43.Mujagić Z, Mujagić H. Diagnostic usefulness of serum carcinoembryonic antigen determinations in breast cancer patients. Bosnian Journal of Basic Medical Sciences 2003; 3 (2): 30-34.

44.Mujagić Z, Mujagić H, Prnjavorac B. Circulating levels of prolactin in breast cancer patients. Med Arch 2005;59 (1):33-35.

45.Mujagić Z, Mujagić H, Prnjavorac B. The relationship between carcinoembryonic antigen (CEA) levels and parameters of primary tumor and metastases in breast cancer patients. Med Arch 2004;58 (1): 23-26.

46.Mujagić Z, Mujagić H, Prnjavorac B. The relationship between circulating carcinoembryonic antigen (CEA) levels and parameters of primary tumor and metastases in breast cancer patients. Med Arch 2004; 58 (1): 23-26

47. Zlata Mujagić, Nahida Srabović, Hamza Mujagic.The role of prolactin in human breast cancer. Biochemia Medica 2009;19(3):236-49.

25

D.International congresses and symposia publications

1.Mujagić H, Kolarić K. The value of immunological skin tests in Oncology. Book of abstracts of the Sec Int Cong Bulgarian Oncol, Varna, 1970. p.104.

2.Mažuran R, Mujagić H, Silobrčić V. Cellular immunity in vitro to melanoma-specific antigens in men detected by the macrophage spreading inhibition test. Book of abstracts of the 3th Europ Immunol Meeting, Amsterdam, 1975. p. 125.

3.Mujagić H, Milas L, Allegretti N, Nola P, Malenica B, Maričić Ž. Immunological reactivity in colorectal carcinoma patients with special reference to the new T-S classification of carcinomas on the colon and rectum. Book of abstracts of the Tenth Int Congr Gastroenter, Budapest, 1976. p. 412.

4.Mujagić H, Dešković M, Malenica B. Tuberculin immunity in cancer patients; clinical and prognostic significance. Bok of abstracts of the 12th Int Cancer Congr, Buenos Aires, 1978. p. 126.

5.Mujagić H, Kolarić K, Nola P. Immunological status in malignant melanoma patients. Book of abstracts of the 12th Int Cancer Congr, Buenos Aires, 1978. p. 188.

6.Mujagić H. Clinical immunological status in malignant melanoma patients. Book of abstracts of the 6th Europ Immunol Meeting, Paris, 1980. p. 188.

7.Mujagić H, Smith CE, Shuette WH, Shackney SE. The cell tubulin content frequency histogram obtained by flow cytometry in sarcoma 180 cells in vitro. Proc Am Assoc Cancer Res, Denver, 1982. p. 105.

8.Chen SS, Occipinti SJ, Mujagić H, Smith CE, Shuette WH, Shackney SE. Multiparameter radiographic image abalysis studies in human lymphomas. Proc Am Assoc Clin Oncol, Denver, 1982. p. 107.

9.Conger B, Occipinti SJ, Mujagić H, Smith CE, Shuette WH, Shackney SE. Studies on lethal and sublethal effects of Vincristine on sarcoma 180 cells in vitro. Proc Am Soc Cell Kin, Houston, 1982. p. 32.

10.Radičević N, Mujagić H. The effect of methylnitrosourea (MNU) on the growth of transplanted methylcholanthrene-induced fibrosarcoma in Balb/c mice. Book of abstracts of the Second World Congress of Pharmacology, Tokyo, 1982. p. 103.

26

11.Radičević N, Mujagić H. The relationship of macrophage spreading inhibition (MSI) with tumor growth and non-specific immunotherapy. Book of abstracts of the 2th World Cong Pharmacol, Tokyo, 1982: Abs.10.5.56.

12.Mujagić H. Tumor-directed immune reactivity in malignant melanoma patients. Book of abstracts of the 2th World Congr Pharmacol, Tokyo, 1982: Abs.10.5.51.

13.Mujagić H, Smith CE, Occipinti S, Shuette WH, Shackney SE. The quantitative changes in immunoglobulin contents on the surface of WEHI-231 lymphoma cells in relation to their proliferative rate. Proc Am Assoc Cancer Res, Atlanta, 1983. p. 32.

14.Curt GA, Bailey BD, Mujagić H, Chabner BA. Pleiotropic drug resistance in MCF-7 human breast carcinoma cell line. Proc Am Assoc Cancer Res, Houston, 1984. p. 104.

15.Petronijević S, Krnjajić N, Jevrić A, Mujagić H. PGF2 alfa levels in pregnant syngeneic Balb/c mice with transplanted methylcholanthrene fibrosarcoma. Joint Meeting Jugosl Finish Pharm, Dubrovnik, 1986. p. 66.

16.Krnjajić N, Petronijević S, Jevrić A, Krnjajić Z, Mujagić H. PGFalfa and PGF2alfa levels in pregnant syngeneic Balb/c mice with transplanted fibrosarcoma. Book of abstracts of the 6th Conf Prostagl Rel Comp, Florence, 1986. p. 206.

17.Krnjaić N, Jevrić A, Mujagić H, Krnjaić Z. The relationship between the levels of PGE1 and PGE2 and macrophage spreading inhibition in tumor bearing mice. 3th Int Symp Prostagland, Bad Ischly, 1986. p. 17.

18.Mujagić Z, Mujagić H. Diagnostic and Prognostic Usefulness of Prolactin (PRL) in Breast Cancer (BC). Proc. ASCO, San Francisco, 2001. p. 20 (43b).

19.Mujagić Z, Mujagić H. Prognostic significance of circulating levels of prolactin (PRL) in metastatic breast cancer (MBC). Proc ASCO, Chicago, 2003. p. 22(49).

20.Mujagic Z, Cicko E, Mujagic H. Circulating levels of prolactin before, during and after surgery in patients under total intravenous and general balanced anesthesia. Proceedings of IMMPC-2, Antalya, Turkey 2004.

27

21.Mujagic Z, Mujagic H. The relationship of circulating prolactin levels to the size of primary tumor in breast cancer patients. Proceedings of the 4th European Conference: «Perspectives in breast cancer», Madrid Spain 2004. p. 22.22.Mujagić H, Milas L. The effect of Corynebacterium parvum on the growth of experimental metastases of fibrosarcoma in the lungs of C57BL mice. Proc Jugosl Immunol Soc, Beograd 1971. p. 68.

23. Milas L, Mujagić H. The growth of experimental metastases of fibrosarcoma in the lungs of splenectomised C57BL mice. Proc Jugosl Immunol Soc, Beograd 1971. p. 67.

24.Mujagić H, Milas L, Malenica B, Jurčić D, Krušić J. Immunological reactivity in patients with rectal carcinoma. Book of abstracts of the Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 77.

25.Malenica B, Mujagić H, Radetić M, Maričić Ž, Roguljić A, Vukas D. BCG immunostimulation in malignant metastatic melanoma patients. Book of abstracts of the Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 30.

26.Mujagić H, Krušić J, Dešković M, Malenica B. Imunološka reaktivnost nespecifične antigene u bolesnica s karcinomom cerviksa. Book of abstracts of the Sixth Congr Jugosl Oncol,Sarajevo, 1975: 35.

27.Mujagić H, Mažuran R, Malenica B, Silobrčić V. Klinička detekcija celularne imunosti na melanomske antigene in vitro testom inhibicije širenja monocita. Book of abstracts of the Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 36.

28.Rogan J, Mujagić H, Malenica B. Citotoksičnost limfocita bolesnika s melanomom. Book of abstracts of the Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 49.

29.Mujagić H, Kolarić K, Malenica B, Popović Š, Maričić Ž. BCG-imunostimulacija bolesnika s malignim melanomom. Book of abstracts of the Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 80.

30.Mujagić H, Djordjević J, Lovrinčević A, Starović B. The extent of disease and frequency of localisation of metastases in malignant

28

melanoma patients. Book of Abstracts of the Int Jugosl Radiol Congr, Novi Sad, 1980. p. 39.

31.Mujagić H, Malenica B, Nola P. Immunological Prophyle in malignant melanoma patients. Book of abstracts of the Sixth Int Cong Iugosl Oncol, Ljubljana, 1980. p.43.

32.Hadžiomerović V, Mujagić H, Bušić I. Immunological characteristics of patients with carcinomas of the head and neck. Book of abstracts of the Sec Int Congr ENT Soc, Niš, 1980. p. 21.

33. Hadžiomerović V, Mujagić H. The combination of Doxorubicin and radiotherapy in the treatment of patients with carcinoma of head and neck. Book of abstracts of the Sixth Int Congr Yugosl Oncol, Ljubljana, 1980. p. 44.

34. Krnjajić A, Jevrić A, Petronijević S, Mujagić H, Krnjajić Z. PGE2 levels in pregnant BaLb/c mice with transplanted methylcholanthrene Fibrosarcoma. Book of abstracts of the Ninth Congr Yugosl Pharm Soc, Beograd, 1985: p. 193.

35.Krnjaić N, Jevrić A, Mujagić H, Petronijević S, Krnjaić Z. PGE1 levels in pregnant syngeneic BALB/c mice with transplanted methylcholantrene fibrosarcoma. Book of abstracts of the 13th Congress of UYPS, Skopje, 1985: Abs. 291.

36.Mujagić H. Liječenje bolesnika sa malignim tumorom u uvjetima promijenjene ekološke sredine. Zbornik radova Simpozija o životnoj sredini, Novi Sad, 1990. p. 17.

37.Mujagić Z, Mujagić H. The relationship between smoking habits and serum prolactin levels in breast cancer patients. Proceedings of the First Bosnia and Herzegovina Congress of Occupational Medicine with International Participations, Tuzla, 2003. p. 242.

38.Mujagić Z, Mujagić H. Circulating levels of prolactin in relation to age in breast cancer patients. Proceedings of the First Bosnia and Herzegovina Congress of Occupational Medicine with International Participations, Tuzla, 2003. p. 256.

29